Preliminary study: Proteomic profiling uncovers potential proteins for biomonitoring equine melanocytic neoplasm

• Main Authors: Parichart Tesena, Amornthep Kingkaw, Wanwipa Vongsangnak, Surakiet Pitikarn, Narumon Phaonakrop, Sittiruk Roytrakul, Attawit Kovitvadhi
• Other Authors: Kasetsart University
• Format: Article
• Published: 2022
• Subjects: Agricultural and Biological Sciences; Veterinary
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/75633
• Institution: Mahidol University

Equine melanocytic neoplasm (EMN) is a cutaneous neoplasm and is mostly observed in aged grey horses. This preliminary study aimed to identify potential proteins to differentiate normal, mild and severe EMN from serum proteomic profiling. Serum samples were collected from 25 grey horses assigned to three groups: normal (free of EMN; n = 10), mild (n = 6) and severe EMN (n = 9). To explore the differences in proteins between groups, proteomic profiling and analysis were employed. Accordingly, 8241 annotated proteins out of 8725 total proteins were compared between normal and EMN groups and inspected based on differentially expressed proteins (DEPs). Through DEP analysis, 95 significant DEPs differed between normal and EMN groups. Among these DEPs, 41 significant proteins were categorised according to protein functions. Based on 41 significant proteins, 10 were involved in metabolism and 31 in non-metabolism. Interestingly, phospholipid phosphatase6 (PLPP6) and ATPase subunit alpha (Na+/K+-ATPase) were considered as potential proteins uniquely expressed in mild EMN and related to lipid and energy metabolism, respectively. Non-metabolism-related proteins (BRCA1, phosphorylase B kinase regulatory subunit: PHKA1, tyrosine-protein kinase receptor: ALK and rho-associated protein kinase: ROCK1) correlated to melanoma development differed among all groups. The results of our study provide a foundation for early EMN biomonitoring and prevention.